Summary
Gilead Sciences, Inc. (GILD) filed an 8-K report on July 31, 2003, to disclose its financial results for the quarter and six months ended June 30, 2003. The primary purpose of this filing was to provide investors with a press release detailing these earnings. The company highlighted its use of non-GAAP financial measures, explaining that these adjustments are intended to provide a clearer view of core operating results and trends by excluding unusual and infrequent charges. Specifically, Gilead emphasized the exclusion of an in-process research and development (IPR&D) charge related to the acquisition of Triangle Pharmaceuticals, Inc. in January 2003. Management believes this adjustment is crucial for investors to understand the underlying performance of the business, as the IPR&D charge was significant and not indicative of ongoing operational performance. This approach aims to offer a more insightful perspective on Gilead's financial health and strategic trajectory.
Key Highlights
- 1Gilead Sciences filed an 8-K on July 31, 2003, to report earnings for the quarter and six months ended June 30, 2003.
- 2The company issued a press release (Exhibit 99.1) detailing its financial results.
- 3Gilead utilized non-GAAP financial measures in its earnings disclosure.
- 4The use of non-GAAP measures was explained as a way to monitor and evaluate ongoing operating results and trends.
- 5A significant in-process research and development (IPR&D) charge related to the Triangle Pharmaceuticals acquisition was excluded.
- 6Management believes excluding the IPR&D charge provides investors with insight into core business operations due to the unusual nature, size, and infrequency of the transaction.
- 7John F. Milligan, Senior Vice President and Chief Financial Officer, signed the report.